Search

Displaying results 1371 - 1380 of 10000 in total
  1. Drug

    Doxercalciferol

    go.drugbank.com/drugs/DB06410
    ApprovedInvestigational

    Doxercalciferol is indicated for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis, as well as for the treatment of secondary hyperparathyroidism in patients … Doxercalciferol is a synthetic vitamin D2 analog that undergoes metabolic activation in vivo to form 1α,25-dihydroxyvitamin D2 (1α,25-(OH)2D2), a naturally occurring, biologically active form of vitamin

  2. Drug

    Terpin hydrate

    go.drugbank.com/drugs/DB13163
    ApprovedWithdrawn

    It was popular in the United States since the late nineteenth century, but was removed from marketed medications in the 1990s after FDA stated that "based on evidence currently available, there are inadequate … Terpin hydrate is an expectorant, commonly used to loosen mucus and ease congestion in patients presenting with acute or chronic bronchitis, and related pulmonary conditions.

  3. Drug

    Neisseria meningitidis serogroup B recombinant LP2086 B01 protein variant antigen

    go.drugbank.com/drugs/DB10285
    ApprovedInvestigational

    It is contained in the suspension of Trumenba, which is a vaccine is composed of two recombinant lipidated factor H binding protein (fHBP) variants from N. meningitidis serogroup B, one from fHBP subfamily

    Mixtures: TRUMENBA SUSPENSION FOR INJECTION IN SINGLE-DOSE PRE-FILLED SYRINGE 0.5ML
  4. Drug

    Gefapixant

    go.drugbank.com/drugs/DB15097
    Approved

    It received approval in both Japan and Switzerland in 2022 for the treatment of adult patients with RCC and UCC, and received subsequent approval in the EU in September 2023 for the same indications. … [L48596,L48591] It is the first therapy to be approved for the treatment of RCC or UCC in the EU.[L48601]

  5. Drug

    Elapegademase

    go.drugbank.com/drugs/DB14712
    Approved

    group in alanine and lysine residues. … [F1937] Elapegademase is generated in _E. coli_, developed by Leadiant Biosciences and FDA approved on October 5, 2018.[L4654,F1939]

    Synonyms: (74-SERINE (C>S),245-THREONINE (A>T))BOS TAURUS ADENOSINE DEAMINASE (BOVINE ADENOSINE AMINOHYDROLASE, EC=3.5.4.4)-(1-356)-PEPTIDE PRODUCED IN ESCHERICHIA COLI, AN AVERAGE OF 13 RESIDUES ARE SUBSTITUTED, (CYS74>SER,ALA245>THR)ADENOSINE DEAMINASE (BOS TAURUS, BOVINE)-(1-356)-PEPTIDE, PRODUCED IN ESCHERICHIA COLI, SUBSTITUTED ON N2 OF THE N-TERMINAL ALANYL RESIDUE (A1) AND ON N6 OF LYSYL RESIDUES (K) WITH
  6. Drug

    Phenelzine

    go.drugbank.com/drugs/DB00780
    ApprovedInvestigational

    [A15753] It was developed by Parke Davis and originally FDA approved on June 9th, 1961. It is currently approved under prescription by the name of Nardil. … Phenelzine, with the formula β-phenylethylhydrazine, is a monoamine oxidase inhibiting antidepressant that is effective in the treatment of panic disorder and social anxiety disorder.

  7. Drug

    Oteseconazole

    go.drugbank.com/drugs/DB13055
    ApprovedInvestigational

    [L41635] CYP51, also known as 14α demethylase, participates in the formation of ergosterol, a compound that plays a vital role in the integrity of cell membranes. … Oteseconazole is an azole metalloenzyme inhibitor that targets fungal CYP51.

  8. Drug

    Xylose

    go.drugbank.com/drugs/DB09419
    ApprovedWithdrawn

    Xylose is a monosaccharide of the aldopentose type consisted of five carbon atoms and an aldehyde functional group. Xylose is a sugar isolated from wood. … D-Xylose is a sugar widely used as a diabetic sweetener in food and beverage. Xylose has also been used as a diagnostic agent to observe malabsorption.

  9. Drug

    Iron protein succinylate

    go.drugbank.com/drugs/DB11209
    Approved

    Mixtures: PR Natal 430 ec, PR Natal 400 ec
  10. Drug

    Setmelanotide

    go.drugbank.com/drugs/DB11700
    ApprovedInvestigational

    [A224449] Imcivree was granted EMA orphan designation on November 19, 2018 [L24559] and FDA approval on November 25, 2020.[L24429] On May 4, 2023, it was approved by Health Canada.[L46327] … [L24474] It is an agonist of the melanocortin 4 receptor.